Clinical Trials Browser

Phase 1/2 × INDUSTRY × zalutumumab × Clear all

NCT00707655 2023-08-03

Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy

Phase 1/2 Terminated

8 enrolled 10 charts

Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT01054625 2023-08-03

Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Phase 1/2 Completed

31 enrolled 16 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT00677924 2023-07-18

GEN206

Phase 1/2 Terminated

9 enrolled 8 charts

Gastrointestinal

Colorectal Neoplasms

NCT00093041 2023-06-28

Zalutumumab in Head and Neck Cancer

Phase 1/2 Completed

28 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT00401401 2011-12-23

Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer

Phase 1/2 Terminated

30 enrolled 13 charts

Head and Neck Neoplasms, Neoplasms, Squamous Cell